SecBot SecBot

APGE

Apogee Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001974640 Biotech & Drug Discovery
No price
Market cap
$10.2B
Large cap
Median target
$135.00
range $133.00–135.11
Short interest
4.20M
≈5.5% of shares · −1.6%
Days to cover
3.5
at average volume
Insider net
−$737.9K
0 buyers · 1 seller · since Jul 14
New fund stakes
0
Q3 2026 13F · 55 exits
Filing reports
23
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $737.9K.

  • InstitutionsBEARISH

    Q3 2026: 1 added (0 new), 55 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.167 → −$1.250 over 90 days. 2 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest −1.6% to 4.20M shares. 3.5 days to cover, ≈5.5% of shares.

Who's buying

13F· Q3 2026
0
new positions
55
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026
Recent actions
DateFirmActionRating
Aug 13, 2026Truist Securities
MAINTAIN
MAINTAINHold
Aug 12, 2026BTIG
DOWNGRADE
DOWNGRADENeutral
Jun 24, 2026Stifel
DOWNGRADE
DOWNGRADEHold
Jun 24, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Jun 24, 2026Guggenheim
DOWNGRADE
DOWNGRADENeutral
Jun 24, 2026Mizuho
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$737.9K
sold · 1 insider
DateInsiderTypeValue
Sep 3, 2026
Fairmount Funds Management LLC
Director
Sep 3, 2026
TO ISSUER6,743,321 sh
Sep 3, 2026
Fairmount Funds Management LLC
Director
Sep 3, 2026
TO ISSUER10,370 sh
Sep 3, 2026
Fairmount Funds Management LLC
Director
Sep 3, 2026
TO ISSUER340,855 sh
Sep 3, 2026
Fairmount Funds Management LLC
Director
Sep 3, 2026
TO ISSUER51,166 sh
Sep 3, 2026
Fairmount Funds Management LLC
Director
Sep 3, 2026
TO ISSUER7,657 sh
Sep 3, 2026
Fairmount Funds Management LLC
Director
Sep 3, 2026
TO ISSUER47,758 sh
Sep 3, 2026
Fairmount Funds Management LLC
Director
Sep 3, 2026
TO ISSUER14,461 sh
Sep 3, 2026
JONES WILLIAM A JR
Director
Sep 3, 2026
TO ISSUER34,824 sh

Earnings setup

Estimates
−$1.25
EPS estimate, this quarter
−7%
estimate change, 90 days
2↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.25-$1.27–-$1.23-8.2%$0.00
Next Q-$1.37-$1.40–-$1.34-10.7%$0.00
Current FY-$4.86-$4.93–-$4.79-10.1%$0.00
Next FY-$5.20-$5.87–-$4.36-0.1%$7.1M

Short side

FINRA· Aug 31, 2026
4,203,052
shares short
-1.6%
vs prior settlement
3.5
days to cover
≈5.5%
of shares outstanding
Trading halts
Sep 2, 2026DeletionResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 Earnings calendar
APGE Q3 2026 Earnings Scheduled · 2026-11-09
Sep 30, 2026 Inst.
MORGAN STANLEY · EXIT
0 shares ($0.00)
Sep 30, 2026 Inst.
BlackRock, Inc. · EXIT
0 shares ($0.00)
Sep 14, 2026 SEC
Apogee Therapeutics has filed a Form 15-12G to terminate its SEC registration and suspend reporting obligations…
15-12G · Impact 4/10
Sep 3, 2026 SEC
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion…
25-NSE · Impact 8/10
Sep 3, 2026 SEC
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion…
8-K · Impact 8/10
Sep 3, 2026 Insider
Fairmount Funds Management LLC disposed of 6,743,321 shares
Director
Sep 3, 2026 Insider
Fairmount Funds Management LLC disposed of 10,370 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

23 filings · 8 press releases · 11 bullish · 1 bearish · 1 mixed · 10 neutral
All APGE filing & press-release reports (31)